CLINICAL TRIALS PROFILE FOR DYANAVEL XR
✉ Email this page to a colleague
All Clinical Trials for DYANAVEL XR
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT03088267 ↗ | Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study | Completed | Tris Pharma, Inc. | Phase 3 | 2017-02-11 | This study was conducted to assess the efficacy and safety of DYANAVEL XR (amphetamine extended-release oral suspension, CII) for the treatment of symptoms of attention-deficit/hyperactivity disorder (ADHD) in children aged 6-12 years. |
NCT03610464 ↗ | Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years | Completed | Tris Pharma, Inc. | Phase 4 | 2018-05-07 | The objective of this study was to evaluate the plasma amphetamine concentration/time profile of amphetamine extended release oral suspension in children aged 4 to 5 years with attention-deficit/hyperactivity disorder, following a single 2.5 mg dose of amphetamine extended release oral suspension. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DYANAVEL XR
Condition Name
Clinical Trial Locations for DYANAVEL XR
Trials by Country
Clinical Trial Progress for DYANAVEL XR
Clinical Trial Phase
Clinical Trial Sponsors for DYANAVEL XR
Sponsor Name